Abstract:The JN.1 variant (BA.2.86.1.1), arising from BA.2.86(.1) with the S:L455S substitution, exhibited increased fitness and outcompeted the previous dominant XBB lineage by the biggening of 2024. JN.1 subsequently diversified, leading to the emergence of descendants with spike (S) protein substitutions such as S:R346T and S:F456L. Particularly, the KP.2 (JN.1.11.1.2) variant, a descendant of JN.1 bearing both S:R346T and S:F456L, is rapidly spreading in multiple regions as of April 2024. Here, we investigated the virological properties of KP.2. KP.2 has three substitutions in the S protein including the two above and additional one substitution in non-S protein compared with JN.1. We estimated the relative effective reproduction number (R ) of KP.2 based on the genome surveillance data from the USA, United Kingdom, and Canada where >30 sequences of KP.2 has been reported, using a Bayesian multinomial logistic model. The R of KP.2 is 1.22-, 1.32-, and 1.26-times higher than that of JN.1 in USA, United Kingdom, and Canada, respectively. These results suggest that KP.2 has higher viral fitness and potentially becomes the predominant lineage worldwide. Indeed, as of the beginning of April 2024, the estimated variant frequency of KP.2 has already reached 20% in United Kingdom. The pseudovirus assay showed that the infectivity of KP.2 is significantly (10.5-fold) lower than that of JN.1. We then performed a neutralization assay using monovalent XBB.1.5 vaccine sera and breakthrough infection (BTI) sera with XBB.1.5, EG.5, HK.3 and JN.1 infections. In all cases, the 50% neutralization titer (NT ) against KP.2 was significantly lower than that against JN.1. Particularly, KP.2 shows the most significant resistance to the sera of monovalent XBB.1.5 vaccinee without infection (3.1-fold) as well as those who with infection (1.8-fold). Altogether, these results suggest that the increased immune resistance ability of KP.2 partially contributes to the higher R more than previous variants including JN.1.

Virological characteristics of the SARS-CoV-2 BA.2.86 variant

Antigenicity and infectivity characterization of SARS-CoV-2 BA.2.86

Structural and functional characteristics of SARS-CoV-2 Omicron subvariant BA.2 spike

Virological characteristics of SARS-CoV-2 Omicron BA.5.2.48

Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike

Virological characteristics of the SARS-CoV-2 JN.1 variant

Virological traits of the SARS-CoV-2 BA.2.87.1 lineage

Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3

Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant

Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1

Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

Comparative analysis of SARS‐CoV‐2 Omicron BA.2.12.1 and BA.5.2 variants

Distinct and Relatively Mild Clinical Characteristics of SARS-CoV-2 BA.5 Infections Against BA.2

Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants

Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants

SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity

Virological characteristics of the SARS-CoV-2 KP.2 variant